External Validation of the International Prognosis Prediction Model of IgA Nephropathy

References

• D’Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med. 1987;64(245):1–8.
   Google Scholar
• Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368(25):2402–2414. doi: 10.1056/NEJMra1206793.
   PubMed Web of Science ®Google Scholar
• Barratt J, Feehally J. IgA nephropathy. J Am Soc Nephrol. 2005;16(7):2088–2097. doi: 10.1681/ASN.2005020134.
   PubMed Web of Science ®Google Scholar
• Lai KN, Tang SC, Schena FP, et al. IgA nephropathy. Nat Rev Dis Primers. 2016;2(1):16001. doi: 10.1038/nrdp.2016.1.
   PubMedGoogle Scholar
• Sallustio F, Curci C, Di Leo V, et al. A new vision of IgA nephropathy: the missing link. Int J Mol Sci. 2019;21(1):189.
   PubMed Web of Science ®Google Scholar
• Reich HN, Troyanov S, Scholey JW, et al. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007;18(12):3177–3183. doi: 10.1681/ASN.2007050526.
   PubMed Web of Science ®Google Scholar
• Magistroni R, D’Agati VD, Appel GB, et al. New developments in the genetics, pathogenesis, and therapy of IgA nephropathy. Kidney Int. 2015;88(5):974–989. doi: 10.1038/ki.2015.252.
   PubMed Web of Science ®Google Scholar
• Barbour SJ, Coppo R, Zhang H, et al. Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med. 2019;179(7):942–952. doi: 10.1001/jamainternmed.2019.0600.
   PubMed Web of Science ®Google Scholar
• Barbour SJ, Reich HN. Risk stratification of patients with IgA nephropathy. Am J Kidney Dis. 2012;59(6):865–873. doi: 10.1053/j.ajkd.2012.02.326.
   PubMed Web of Science ®Google Scholar
• Lv J, Shi S, Xu D, et al. Evaluation of the Oxford classification of IgA nephropathy: a systematic review and meta-analysis. Am J Kidney Dis. 2013;62(5):891–899. doi: 10.1053/j.ajkd.2013.04.021.
   PubMed Web of Science ®Google Scholar
• Trimarchi H, Barratt J, Cattran DC, et al. Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group. Kidney Int. 2017;91(5):1014–1021. doi: 10.1016/j.kint.2017.02.003.
   PubMed Web of Science ®Google Scholar
• Cattran DC, Coppo R, Cook HT, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76(5):534–545. doi: 10.1038/ki.2009.243.
   PubMed Web of Science ®Google Scholar
• Collins GS, Reitsma JB, Altman DG, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015;350(jan07 4):g7594–g7594. doi: 10.1136/bmj.g7594.
   PubMed Web of Science ®Google Scholar
• Zhang J, Huang B, Liu Z, et al. External validation of the international IgA nephropathy prediction tool. Clin J Am Soc Nephrol. 2020;15(8):1112–1120. doi: 10.2215/CJN.16021219.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Guo L, Wang Z, et al. External validation of international risk-prediction models of IgA nephropathy in an Asian-Caucasian cohort. Kidney Int Rep. 2020;5(10):1753–1763. doi: 10.1016/j.ekir.2020.07.036.
   PubMed Web of Science ®Google Scholar
• Ramspek CL, Jager KJ, Dekker FW, et al. External validation of prognostic models: what, why, how, when and where? Clin Kidney J. 2021;14(1):49–58. doi: 10.1093/ckj/sfaa188.
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612. doi: 10.7326/0003-4819-150-9-200905050-00006.
   PubMed Web of Science ®Google Scholar
• Moons KG, Altman DG, Reitsma JB, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015;162(1):W1–73. doi: 10.7326/M14-0698.
   PubMed Web of Science ®Google Scholar
• Rodrigues JC, Haas M, Reich HN. IgA nephropathy. Clin J Am Soc Nephrol. 2017;12(4):677–686. doi: 10.2215/CJN.07420716.
   PubMed Web of Science ®Google Scholar
• Okonogi H, Utsunomiya Y, Miyazaki Y, et al. A predictive clinical grading system for immunoglobulin a nephropathy by combining proteinuria and estimated glomerular filtration rate. Nephron Clin Pract. 2011;118(3):c292–300. doi: 10.1159/000322613.
   PubMedGoogle Scholar
• Xie J, Kiryluk K, Wang W, et al. Predicting progression of IgA nephropathy: new clinical progression risk score. PLoS One. 2012;7(6):e38904. doi: 10.1371/journal.pone.0038904.
   PubMed Web of Science ®Google Scholar
• Pesce F, Diciolla M, Binetti G, et al. Clinical decision support system for end-stage kidney disease risk estimation in IgA nephropathy patients. Nephrol Dial Transplant. 2016;31(1):80–86. doi: 10.1093/ndt/gfv232.
   PubMed Web of Science ®Google Scholar
• Goto M, Kawamura T, Wakai K, et al. Risk stratification for progression of IgA nephropathy using a decision tree induction algorithm. Nephrol Dial Transplant. 2009;24(4):1242–1247. doi: 10.1093/ndt/gfn610.
   PubMed Web of Science ®Google Scholar
• Chen T, Li X, Li Y, et al. Prediction and risk stratification of kidney outcomes in IgA nephropathy. Am J Kidney Dis. 2019;74(3):300–309. doi: 10.1053/j.ajkd.2019.02.016.
   PubMed Web of Science ®Google Scholar
• Tripepi G, Heinze G, Jager KJ, et al. Risk prediction models. Nephrol Dial Transplant. 2013;28(8):1975–1980. doi: 10.1093/ndt/gft095.
   PubMed Web of Science ®Google Scholar
• Knoop T, Vikse BE, Mwakimonga A, et al. Long-term outcome in 145 patients with assumed benign immunoglobulin a nephropathy. Nephrol Dial Transplant. 2017;32(11):1841–1850. doi: 10.1093/ndt/gfx242.
   PubMed Web of Science ®Google Scholar
• Floege J, Wied S, Rauen T. Assessing prognosis in IgA nephropathy. Kidney Int. 2022;102(1):22–24. doi: 10.1016/j.kint.2022.04.018.
   PubMed Web of Science ®Google Scholar
• Wang RX, Liao BQ, Chen W, et al. A meta-analysis of effects and safety of tripterygium wilfordii polyglycoside in the treatment of IgA nephropathy. Eur Rev Med Pharmacol Sci. 2022;26(23):8756–8770.
   PubMed Web of Science ®Google Scholar
• Chen YZ, Gao Q, Zhao XZ, et al. Meta-analysis of tripterygium Wilfordii Hook F in the immunosuppressive treatment of IgA nephropathy. Intern Med. 2010;49(19):2049–2055. doi: 10.2169/internalmedicine.49.3704.
   PubMed Web of Science ®Google Scholar
• Zhao L, Lan Z, Peng L, et al. Triptolide promotes autophagy to inhibit mesangial cell proliferation in IgA nephropathy via the CARD9/p38 MAPK pathway. Cell Prolif. 2022;55(9):e13278. doi: 10.1111/cpr.13278.
   PubMed Web of Science ®Google Scholar